| Primary |
| Hypertension |
20.1% |
| Cardiac Failure |
14.2% |
| Product Used For Unknown Indication |
10.8% |
| Drug Use For Unknown Indication |
7.8% |
| Prophylaxis |
7.4% |
| Atrial Fibrillation |
5.4% |
| Ascites |
4.4% |
| Cardiac Failure Congestive |
4.4% |
| Diabetes Mellitus |
3.4% |
| Renal Failure Chronic |
3.4% |
| Depression |
2.9% |
| Cardiovascular Event Prophylaxis |
2.5% |
| Arrhythmia |
2.0% |
| Essential Hypertension |
2.0% |
| Hepatic Cirrhosis |
2.0% |
| Oedema |
2.0% |
| Atrial Flutter |
1.5% |
| Hyperuricaemia |
1.5% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.5% |
| Anaemia |
1.0% |
|
| Renal Failure Acute |
43.1% |
| Hyponatraemia |
8.6% |
| Encephalopathy |
6.9% |
| Cardiovascular Disorder |
5.2% |
| Renal Failure Chronic |
5.2% |
| Hepatic Encephalopathy |
3.4% |
| Hypercalcaemia |
3.4% |
| Somnolence |
3.4% |
| Bradycardia |
1.7% |
| Drug Interaction |
1.7% |
| Heart Rate Decreased |
1.7% |
| Hepatitis Acute |
1.7% |
| Hepatitis Cholestatic |
1.7% |
| Hypernatraemia |
1.7% |
| Inappropriate Antidiuretic Hormone Secretion |
1.7% |
| Lactic Acidosis |
1.7% |
| Nausea |
1.7% |
| Off Label Use |
1.7% |
| Orthostatic Hypotension |
1.7% |
| Renal Tubular Necrosis |
1.7% |
|
| Secondary |
| Drug Use For Unknown Indication |
30.7% |
| Hypertension |
14.1% |
| Cardiomyopathy |
7.6% |
| Cough |
7.2% |
| Product Used For Unknown Indication |
4.7% |
| Renal Transplant |
4.7% |
| Cardiac Failure Congestive |
4.0% |
| Cardiac Disorder |
3.6% |
| Cardiac Failure |
3.6% |
| Diabetes Mellitus |
2.9% |
| Blood Test Abnormal |
2.2% |
| Dyslipidaemia |
1.8% |
| Hepatic Cirrhosis |
1.8% |
| Hyperuricaemia |
1.8% |
| Iron Deficiency Anaemia |
1.8% |
| Prophylaxis |
1.8% |
| Cardiovascular Event Prophylaxis |
1.4% |
| Coronary Artery Disease |
1.4% |
| Depression |
1.4% |
| Gastric Ulcer |
1.4% |
|
| Renal Failure Acute |
18.8% |
| Stevens-johnson Syndrome |
17.2% |
| Toxic Epidermal Necrolysis |
7.8% |
| Hepatic Encephalopathy |
6.3% |
| Hyponatraemia |
6.3% |
| Somnolence |
4.7% |
| Vomiting |
4.7% |
| Drug Interaction |
3.1% |
| Ileus Paralytic |
3.1% |
| Lactic Acidosis |
3.1% |
| Mutism |
3.1% |
| Pancreatitis Necrotising |
3.1% |
| Petechiae |
3.1% |
| Rash Papulosquamous |
3.1% |
| Renal Tubular Necrosis |
3.1% |
| Troponin Increased |
3.1% |
| Agranulocytosis |
1.6% |
| Cardiovascular Disorder |
1.6% |
| Dyspnoea |
1.6% |
| Helicobacter Pylori Identification Test Positive |
1.6% |
|
| Concomitant |
| Hypertension |
16.3% |
| Osteoporosis |
10.3% |
| Drug Use For Unknown Indication |
9.7% |
| Atrial Fibrillation |
9.2% |
| Pain |
7.7% |
| Prophylaxis |
7.5% |
| Cardiac Failure |
5.4% |
| Product Used For Unknown Indication |
5.0% |
| Hiv Infection |
3.9% |
| Diabetes Mellitus |
3.6% |
| Cardiac Disorder |
3.5% |
| Multiple Myeloma |
2.6% |
| Type 2 Diabetes Mellitus |
2.5% |
| Arrhythmia |
2.0% |
| Oedema |
2.0% |
| Chronic Obstructive Pulmonary Disease |
1.9% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.9% |
| Diuretic Therapy |
1.8% |
| Ascites |
1.7% |
| Hypothyroidism |
1.7% |
|
| Hyperkalaemia |
12.1% |
| Renal Failure Acute |
9.3% |
| Urinary Tract Infection |
7.1% |
| Renal Failure |
5.7% |
| Respiratory Failure |
5.7% |
| Vomiting |
5.7% |
| General Physical Health Deterioration |
5.0% |
| Hepatic Failure |
5.0% |
| Renal Failure Chronic |
5.0% |
| Pyrexia |
4.3% |
| Syncope |
4.3% |
| Therapeutic Agent Toxicity |
4.3% |
| Weight Decreased |
4.3% |
| Tachycardia |
3.6% |
| Thrombocytopenia |
3.6% |
| Tremor |
3.6% |
| Drug Interaction |
2.9% |
| Gastritis Erosive |
2.9% |
| Lactic Acidosis |
2.9% |
| Myocardial Infarction |
2.9% |
|
| Interacting |
| Hypertension |
24.4% |
| Ascites |
12.0% |
| Cardiac Failure |
10.7% |
| Drug Use For Unknown Indication |
6.0% |
| Hepatic Cirrhosis |
6.0% |
| Chronic Hepatitis |
5.6% |
| Depression |
5.1% |
| Prophylaxis |
3.8% |
| Atrial Fibrillation |
3.4% |
| Acute Coronary Syndrome |
3.0% |
| Cirrhosis Alcoholic |
2.6% |
| Diabetes Mellitus |
2.6% |
| Product Used For Unknown Indication |
2.6% |
| Cardiac Failure Congestive |
2.1% |
| Anxiety |
1.7% |
| Cardiac Failure Chronic |
1.7% |
| Hypertrophic Cardiomyopathy |
1.7% |
| Pulmonary Hypertension |
1.7% |
| Renal Failure Chronic |
1.7% |
| Thrombosis Prophylaxis |
1.7% |
|
| Hepatic Encephalopathy |
32.9% |
| Renal Failure Acute |
28.0% |
| Hyponatraemia |
8.5% |
| Drug Interaction |
6.1% |
| Encephalopathy |
3.7% |
| Nausea |
3.7% |
| Renal Failure Chronic |
3.7% |
| Therapeutic Agent Toxicity |
3.7% |
| Inappropriate Antidiuretic Hormone Secretion |
2.4% |
| Epistaxis |
1.2% |
| Renal Impairment |
1.2% |
| Somnolence |
1.2% |
| Toxicity To Various Agents |
1.2% |
| Uraemic Encephalopathy |
1.2% |
| Urosepsis |
1.2% |
|
